Trials / Terminated
TerminatedNCT01382745
Nimotuzumab With Radiotherapy in the Treatment of Anal Canal Cancers
A Phase II Clinical Study Using Nimotuzumab in Combination With External Beam Radiation Therapy in the Treatment of Patients With Carcinomas of the Anal Canal
- Status
- Terminated
- Phase
- Phase 2
- Study type
- Interventional
- Enrollment
- 1 (actual)
- Sponsor
- Dr. Te Vuong · Academic / Other
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
The objective of this study is to demonstrate the feasibility of using Nimotuzumab and radiation in the treatment of squamous cell carcinomas of the anal canal in order to achieve a 65% local control rate with a better toxicity profile than the conventional treatment. Patients with high toxicity risks (HIV+ and fragile patients) will be selected for this study.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Nimotuzumab | 200mg Nimotuzumab once a week for 12 weeks |
| RADIATION | Intensity Modulated Radiation Therapy (IMRT) | IMRT radiation therapy with doses varying from 45Gy-54Gy in 25-30 fractions |
Timeline
- Start date
- 2012-01-01
- Primary completion
- 2021-09-01
- Completion
- 2022-01-01
- First posted
- 2011-06-27
- Last updated
- 2013-01-28
Locations
1 site across 1 country: Canada
Source: ClinicalTrials.gov record NCT01382745. Inclusion in this directory is not an endorsement.